The Promise of Gene Therapy - Quiz - MDSpire

The Promise of Gene Therapy

With phase 3 topline data for sura-vec expected later this year, Arshad M. Khanani, MD, FASRS, reflects on how gene therapy could transform long-term treatment for nAMD.

  • By

  • Arshad M. Khanani, MD, MA, FASRS

  • July 15, 2026

  • 2 min

Share

Original Source(s)

The Promise of Gene Therapy

  • by Arshad M. Khanani, MD, MA, FASRS

  • July 15, 2026

Related Content

The Economics of Home OCT

At ASRS 2026, Sean Berkowitz, MD, MBA, examined the payer costs and physician workload associated with home OCT monitoring for wet AMD.

Neuroprotection: Retina's Next Frontier?

At OIS Retina in Montreal, Riad Sherif, MD, discussed Oculis’s optic neuritis program and why neuroprotection may represent the next frontier in retinal therapeutics.

Can Patients Switch to Biosimilar Aflibercept?

A 20-week INSIGHT extension suggests that switching from reference aflibercept to MYL-1701P maintained comparable safety, visual, and anatomic outcomes in patients with diabetic macular edema.